Relapse After Treatment Withdrawal in Autoimmune Hepatitis: Biopsy‐Guided Versus Clinically Guided Strategies—A Meta‐Analysis
- 20 April 2026
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 46 (5) , e70642
Abstract
Long‐term immunosuppression in autoimmune hepatitis (AIH) carries substantial side effects, making treatment withdrawal an important consideration after sustained biochemical remission. Whether biopsy‐guided withdrawal based on histological assessment reduces relapse compared with clinically guided withdrawal remains uncertain. We conducted a systematic review and meta‐analysis to compare relapse rates between these two strategies. This meta‐analysis followed PRISMA 2020. PubMed, Embase, Web of Science, Scopus and the Cochrane Library were searched from inception to identify studies reporting relapse after treatment withdrawal in AIH using biopsy‐guided or clinically guided strategies. Pooled relapse rates were estimated using random‐effects models of transformed proportions. Prespecified subgroup, sensitivity and meta‐regression analyses evaluated the impact of relapse definitions, histological stringency and follow‐up duration. Twelve studies (518 patients) were included. The pooled relapse rate after treatment withdrawal was 51.1%. Relapse rates were not significantly different between biopsy‐guided (48.3%) and clinically guided withdrawal (56.3%; p = 0.604). Studies defining relapse by transaminase elevation alone reported higher relapse rates than those incorporating IgG elevation. Within biopsy‐guided cohorts, stricter histological remission thresholds were associated with lower relapse rates and reduced heterogeneity.Relapse after treatment withdrawal in AIH remained common and did not differ significantly between biopsy‐guided and clinically guided strategies. In the context of existing guideline recommendations, current evidence does not clearly support routine prewithdrawal liver biopsy in all patients with sustained biochemical remission. Trial Registration: PROSPERO registration number: 4202511295Keywords
Funding Information
- National Natural Science Foundation of China (No.ZYGD23031)
This publication has 29 references indexed in Scilit:
- EASL Clinical Practice Guidelines on the management of autoimmune hepatitisJournal of Hepatology, 2025
- The impact of continuity correction methods in Cochrane reviews with single‐zero trials with rare events: A meta‐epidemiological studyResearch Synthesis Methods, 2024
- Treatment response and clinical event-free survival in autoimmune hepatitis: A Canadian multicentre cohort studyJournal of Hepatology, 2024
- Noninvasive biomarkers for the diagnosis and management of autoimmune hepatitisHepatology, 2022
- Best practice guidelines for France regarding the diagnosis and management of autoimmune hepatitisClinics and Research in Hepatology and Gastroenterology, 2022
- The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitisHepatology International, 2021
- Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver DiseasesHepatology, 2019
- Autoimmune hepatitis in Italy: The Bologna experienceJournal of Hepatology, 2009
- Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitisJournal of Hepatology, 2005
- How should meta‐regression analyses be undertaken and interpreted?Statistics in Medicine, 2002